![](https://nta.org/wp-content/uploads/2024/07/Prototype-MCMs-to-address-the-therapeutic-indications-of-the-Warfighter-exposure-to-viral-and-bacterial-biothreat-agents-1024x770.webp)
Anticipated Release Date: Q4FY24
The prioritizations on broad-spectrum direct-acting antivirals (nucleoside/nucleotide-like compounds and combination therapies) and host-directed broad-spectrum antivirals and antibacterials such as molecules that target host signaling pathways, are involved in entry and replication, epigenetic modifications in the host, and modulation of host response.
Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.